Trial
NCT01779167
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Celgene Corporation
Condition
Waldenstrom Macroglobulinemia
Intervention
Thalidomide
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-11